Menu
Your Cart

Apostle MiniEnrich NanoBlockers (for Illumina®), 96 rxn

Apostle MiniEnrich NanoBlockers (for Illumina®), 96 rxn
Secured Shopping
Best security features
Apostle MiniEnrich NanoBlockers (for Illumina®), 96 rxn

Introduction

Apostle MiniEnrich NanoBlockers are optimized blockers for MGI/Illumina platforms based on Apostle MiniEnrich Hybrid Capture System. The Apostle MiniEnrich NanoBlockers facilitates better binding of the library's adapter sequences to the sequencing platform. This reduces non-specific binding between adapters, resulting in improved on-target rates and increased data utilization. Apostle MiniEnrich NanoBlockers can be used to block the adapters with 6-10 nt index in the library.

 

Feature

o   Precise detection of large-scale CpG sites: Simultaneously assessment of multiple genes' CpG sites associated with various cancers, achieving precise comprehensive joint testing

o   Accurate quantification of methylation levels: High-precision coverage for accurate quantification of different methylation states ranging from 0 to 100% in various samples

o   Fast and convenient operation: Simplified experimental procedures, and user-friendly operations, completing the entire process within same day

o   Highly efficient and stable: Avoid inconsistent amount of raw data, ensuring stability in capture sequencing results, thereby reducing the risk of rework

o   Cost-effective sequencing: Utilize a mixed hybrid mode to reduce the quantity of hybrid reaction, lower sequencing costs and enhance cost-effectiveness

 

Information

Cat #

NA003122

Capacity

96 rxn

Performance

Check information page

Protocol

Download

$3,000.00
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.